Published in Cancer Res on August 01, 1995
DNA copy number losses in human neoplasms. Am J Pathol (1999) 2.73
MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res (2009) 2.59
Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays. Int J Cancer (2009) 1.33
Somatic mutation of PTEN in bladder carcinoma. Br J Cancer (1999) 1.24
What we could do now: molecular pathology of bladder cancer. Mol Pathol (2001) 1.22
Molecular differential diagnosis of renal cell carcinomas by microsatellite analysis. Am J Pathol (1996) 1.17
Chromosome 14 transfer and functional studies identify a candidate tumor suppressor gene, mirror image polydactyly 1, in nasopharyngeal carcinoma. Proc Natl Acad Sci U S A (2009) 0.88
miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity. Oncotarget (2015) 0.87
Genomic alterations in nasopharyngeal carcinoma: loss of heterozygosity and Epstein-Barr virus infection. Br J Cancer (1997) 0.87
Deletions at 14q in malignant mesothelioma detected by microsatellite marker analysis. Br J Cancer (1999) 0.83
Evidence for two candidate tumour suppressor loci on chromosome 9q in transitional cell carcinoma (TCC) of the bladder but no homozygous deletions in bladder tumour cell lines. Br J Cancer (1999) 0.82
Concomitant downregulation of the imprinted genes DLK1 and MEG3 at 14q32.2 by epigenetic mechanisms in urothelial carcinoma. Clin Epigenetics (2014) 0.80
p53 mutations in human cancers. Science (1991) 31.96
Participation of p53 protein in the cellular response to DNA damage. Cancer Res (1991) 16.00
Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst (2000) 14.43
5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med (1995) 9.10
Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res (1995) 7.42
Head and neck cancer. N Engl J Med (2001) 7.32
Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med (1995) 5.10
Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res (1996) 4.89
Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science (2000) 4.87
Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res (1997) 4.73
AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci U S A (2000) 4.37
Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res (1998) 4.33
Mitochondrial DNA mutations in human cancer. Oncogene (2006) 4.08
Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet (1995) 3.76
DPC4 gene in various tumor types. Cancer Res (1996) 3.74
Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med (1995) 3.31
Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer (2001) 3.22
High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res (1996) 3.18
Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res (1997) 3.17
Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res (1999) 3.15
Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res (2000) 2.99
p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res (1993) 2.99
Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med (1996) 2.95
Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst (2001) 2.93
Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res (2000) 2.79
Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet (1994) 2.65
Role of the p16 tumor suppressor gene in cancer. J Clin Oncol (1998) 2.51
Isolated ductus arteriosus aneurysm in the fetus and infant: a multi-institutional experience. J Am Coll Cardiol (2000) 2.36
p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res (2001) 2.34
Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst (1999) 2.34
Brief report: molecular biology and the early detection of carcinoma of the bladder--the case of Hubert H. Humphrey. N Engl J Med (1994) 2.22
A new human p53 homologue. Nat Med (1998) 2.21
Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res (2001) 2.18
Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science (1994) 2.16
Hypernatraemia: why bother weighing breast fed babies? Arch Dis Child Fetal Neonatal Ed (2001) 2.13
Identification of a mononucleotide repeat as a major target for mitochondrial DNA alterations in human tumors. Cancer Res (2001) 2.10
Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. Proc Natl Acad Sci U S A (1999) 2.08
The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res (1993) 2.05
Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst (2001) 2.04
Detection of mitochondrial DNA mutations in primary breast cancer and fine-needle aspirates. Cancer Res (2001) 1.98
Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res (2000) 1.91
Microsatellite alterations as clonal markers for the detection of human cancer. Proc Natl Acad Sci U S A (1994) 1.81
Recommended biocontainment features for research and diagnostic facilities where animal pathogens are used. First International Veterinary Biosafety Workshop. Rev Sci Tech (1995) 1.81
Multiple head and neck tumors: evidence for a common clonal origin. Cancer Res (1996) 1.80
Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst (1998) 1.78
Capromab Pendetide imaging of prostate cancer. Cancer Biother Radiopharm (2000) 1.75
A novel p16INK4A transcript. Cancer Res (1995) 1.74
Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. Cancer Res (1998) 1.71
Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin Cancer Res (2001) 1.71
Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res (1994) 1.68
Serial analysis of gene expression in non-small cell lung cancer. Cancer Res (1998) 1.67
Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res (2001) 1.67
Mitochondrial mutations in early stage prostate cancer and bodily fluids. Oncogene (2001) 1.66
Genetic divergence in the clonal evolution of breast cancer. Cancer Res (1996) 1.63
Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin Cancer Res (2001) 1.63
Infrequent p53 gene mutations in medulloblastomas. Cancer Res (1991) 1.62
Microsatellite instability at AAAG repeat sequences in respiratory tract cancers. Int J Cancer (2001) 1.62
Diagnosis of renal cancer by molecular urinalysis. J Natl Cancer Inst (1999) 1.60
Gender differences in stage-adjusted bladder cancer survival. Urology (2000) 1.55
Head and neck cancer in nonsmokers: a distinct clinical and molecular entity. Laryngoscope (1999) 1.55
Molecular characteristics of non-small cell lung cancer. Proc Natl Acad Sci U S A (2001) 1.53
Management of small renal tumors: an overview. Am J Med (2001) 1.48
Allelotype of head and neck squamous cell carcinoma. Cancer Res (1994) 1.47
Detection and quantitation of human papillomavirus (HPV) DNA in the sera of patients with HPV-associated head and neck squamous cell carcinoma. Clin Cancer Res (2000) 1.46
Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst (2000) 1.45
Molecular detection of primary bladder cancer by microsatellite analysis. Science (1996) 1.44
Frequent microsatellite instability in primary small cell lung cancer. Cancer Res (1994) 1.44
Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. Genes Chromosomes Cancer (1997) 1.42
Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res (1994) 1.40
Detection of head and neck squamous cell carcinoma among exfoliated oral mucosal cells by microsatellite analysis. Clin Cancer Res (2001) 1.39
Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene (1998) 1.36
PGP9.5 as a candidate tumor marker for non-small-cell lung cancer. Am J Pathol (1999) 1.36
Selective radiosensitization of p53-deficient cells by caffeine-mediated activation of p34cdc2 kinase. Nat Med (1996) 1.35
Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. Cancer Res (2001) 1.34
p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J Natl Cancer Inst (1996) 1.32
Microsatellite instability at selected tetranucleotide repeats is associated with p53 mutations in non-small cell lung cancer. Cancer Res (2000) 1.30
BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood (1995) 1.30
Molecular detection of genetic alterations in the serum of colorectal cancer patients. Cancer Res (1998) 1.29
Quantitative assessment of promoter methylation profiles in thyroid neoplasms. J Clin Endocrinol Metab (2005) 1.27
Phospho-ΔNp63α is a key regulator of the cisplatin-induced microRNAome in cancer cells. Cell Death Differ (2011) 1.26
Detection of tumor mutations in the presence of excess amounts of normal DNA. Nat Biotechnol (2002) 1.22
Homozygous deletions of 9p21 in primary human bladder tumors detected by comparative multiplex polymerase chain reaction. Cancer Res (1994) 1.21
NID2 and HOXA9 promoter hypermethylation as biomarkers for prevention and early detection in oral cavity squamous cell carcinoma tissues and saliva. Cancer Prev Res (Phila) (2011) 1.21
Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell Death Differ (2010) 1.21
p16 and p16 beta are potent growth suppressors of head and neck squamous carcinoma cells in vitro. Cancer Res (1996) 1.19
Cardiac presentation of non-Hodgkin's lymphoma. Arch Pathol Lab Med (1987) 1.19
Genetic alterations in urinary bladder carcinosarcoma: evidence of a common clonal origin. Eur Urol (2000) 1.18